Efficacy of combined treatment with alendronate ALN and eldecalcitol, a new active vitamin D analog, compared to that of concomitant ALN, vitamin D plus calcium treatment in Japanese patients with primary osteoporosisReport as inadecuate




Efficacy of combined treatment with alendronate ALN and eldecalcitol, a new active vitamin D analog, compared to that of concomitant ALN, vitamin D plus calcium treatment in Japanese patients with primary osteoporosis - Download this document for free, or read online. Document in PDF available to download.

Osteoporosis International

, Volume 26, Issue 3, pp 1193–1202

First Online: 16 January 2015Received: 06 October 2014Accepted: 05 December 2014

Abstract

SummaryCombined treatment with alendronate and eldecalcitol was found to be more effective in reducing the bone turnover markers and increasing bone mineral density than alendronate treatment with vitamin D3 and calcium supplementation in the osteoporotic patients.

IntroductionWe compared the clinical efficacy and safety of combined treatment with alendronate plus eldecalcitol ALN + ELD with those of treatment with ALN plus vitamin D and calcium ALN + VitD.

MethodsOsteoporotic 219 patients were randomly assigned to the ALN + ELD, or the ALN + VitD group. Primary endpoint was the inter-group differences in lumbar spine BMD L-BMD at patient’s last visit. Secondary endpoints included the differences in BMD at other sites and the bone turnover marker BTM levels.

ResultsL-BMD, total hip BMD and femoral neck FN-BMD increased from baseline by 7.30, 2.41, and 2.70 % in the ALN + ELD group, and by 6.52, 2.27, and 1.18 % in the ALN + VitD group, respectively. Inter-group differences of the L-BMD and total hip BMD values were not significant. The increase of the FN-BMD was larger in the ALN + ELD group than the ALN + VitD group. Reductions of the BTMs were greater in the ALN + ELD group than the ALN + VitD group. Interaction of the percent increase of the L-BMD with the baseline values of the BTMs was observed in the ALN + VitD group only. The increases of the FN-BMD in patients with lower baseline values of type-I-collagen C-telopeptide sCTX and serum 25OH D levels <20 ng-mL were significantly larger in the ALN + ELD group than the other group.

ConclusionCombination treatment of ALN plus ELD was more effective in reducing the BTMs and increasing the FN-BMD than ALN treatment with vitamin D3 and calcium.

KeywordsBisphosphonate Bone mineral density Bone turnover markers Eldecalcitol Vitamin D e-ADVANCED Study = Eldecalcitol; Alendronate plus vitamin D Vs. AleNdronate Combined with ElDecalcitol Study

An erratum to this article can be found at http:-dx.doi.org-10.1007-s00198-015-3049-6.

Download fulltext PDF



Author: A. Sakai - M. Ito - T. Tomomitsu - H. Tsurukami - S. Ikeda - F. Fukuda - H. Mizunuma - T. Inoue - H. Saito - T. Nakamura

Source: https://link.springer.com/



DOWNLOAD PDF




Related documents